中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

艾滋病病毒/丙型肝炎病毒双重感染者的艾滋病病毒特异性CTL应答

康文臻 黄德东 李媛 庄严 翟嵩 赵柯 谢玉梅 孙永涛

引用本文:
Citation:

艾滋病病毒/丙型肝炎病毒双重感染者的艾滋病病毒特异性CTL应答

基金项目: 

国家科技重大专项“十一五”计划资助(2008ZX10001-008); 

详细信息
  • 中图分类号: R512.63;R512.91

HIV-specific cytotoxic T-lymphocyte responses in patients co-infected with HIV and HCV

Research funding: 

 

  • 摘要:

    目的探讨中国艾滋病病毒/丙型肝炎病毒(HIV/HCV)双重感染患者HIV特异性细胞毒性T淋巴细胞(CTL)应答的特征。方法观察对象为HIV/HCV双重患者、单纯HIV感染者。以HIV-1 B亚型构建的全基因组肽库作为抗原,通过酶联免疫斑点(ELISPOT)法检测HIV/AIDS患者HIV特异性CTL应答。并对HIV/HCV双重感染患者的HIV特异性CTL应答进行相关性分析。结果 HIV/HCV双重感染组和单纯HIV感染组的HIV特异性CTL应答强度与频率在肽段水平存在一定差异,与单纯HIV感染组相比,合并HCV感染组反应增强的肽段主要集中在Gag。两组特异性CTL应答强度与频率均呈明显正相关,且合并HCV感染组较单纯感染组正相关性增强。不同肽段累计反应强度的比较,Gag反应强度最高,其次是Nef。CD4计数与特异性CTL应答强度的关系无统计学意义。结论 HIV/HCV双重感染患者HCV对HIV进程的影响可能与对Gag蛋白CTL应答的增强有关。

     

  • [1]Verucchi G, Calza L, Manfredi R, et al.Humanimmunodeficiency virus and hepatitis C virus coinfection:epidemiology, natural history, therapeutic options andclinical management[J].Infection, 2004, 32 (1) :33-46.
    [2]Dodig M, Tavill AS.Hepatitis C and humanimmunodeficiency virus coinfections[J].J ClinGastroenterol, 2001, 33 (5) :367-374.
    [3]Zhai S, Zhuang Y, Song Y, et al.HIV-1-specific cytotoxicT lymphocyte (CTL) responses against immunodominantoptimal epitopes slow the progression of AIDS inChina[J].Curr HIV Res, 2008, 6 (4) :335-350.
    [4]Graham CS, Baden LR, Yu E, et al.Influence of human immunodeficiency virus infection on the course ofhepatitis C virus infection:a meta-analysis[J].Clin InfectDis, 2001, 33 (4) :562-569.
    [5]Rotman Y, Liang TJ.Coinfection with hepatitis Cvirus and human immunodeficiency virus:virological, immunological, and clinical outcomes[J].J Virol, 2009, 83 (15) :7366-7374.
    [6]Bonacini M, Louie S, Bzowej N, et al.Survival in patientswith HIV infection and viral hepatitis B or C:a cohortstudy[J].AIDS, 2004, 18 (15) :2039-2045.
    [7]Lincoln D, Petoumenos K, Dore GJ.HIV/HBV and HIV/HCV coinfection, and outcomes following highly activeantiretroviral therapy[J].HIV Med, 2003, 4 (3) :241-249.
    [8]刘静, 姜拥军, 张, 等.HCV-RNA水平对HIV/HCV合并感染者HIV疾病进展影响研究[J].中华微生物学和免疫学杂志, 2008, 28 (6) :503-507.
    [9]Fierer DS, Uriel AJ, Carriero DC, et al.Liver fibrosis duringan outbreak of acute hepatitis C virus infection in HIV-infected men:a prospective cohort study[J].J Infect Dis, 2008, 198 (5) :683-686.
    [10]Soriano V, Puoti M, Sulkowski M, et al.Care of patientswith hepatitis C and HIV co-infection[J].AIDS, 2004, 18 (1) :1-12.
    [11]Addo MM, Yu XG, Rathod A, et al.Comprehensive ep-itope analysis of human immunodeficiency virus type 1 (HIV-1) -specific T-cell responses directed against theentire expressed HIV-1 genome demonstrate broadlydirected responses, but no correlation to viral load[J].JVirol, 2003, 77 (3) :2081-2092.
    [12]De Francesco R, Migliaccio G.Challenges and succe-sses in developing new therapies for hepatitis C[J].Nature, 2005, 436 (7053) :953-960.
    [13]Meier V, Ramadori G.Hepatitis C virus virology and newtreatment targets[J].Expert Rev Anti Infect Ther, 2009, 7 (3) :329-350.
    [14]Morikawa Y, Zhang WH, Hockley DJ, et al.Detection ofa trimeric human immunodeficiency virus type 1 Gagintermediate is dependent on sequences in the matrixprotein, p17[J].J Virol, 1998, 72 (9) :7659-7663.
    [15]Kelleher AD, Long C, Holmes EC, et al.Clusteredmutations in HIV-1 gag are consistently required forescape from HLA-B27-restricted cytotoxic T lymphocyteresponses[J].J Exp Med, 2001, 193 (3) :375-386.
  • 加载中
计量
  • 文章访问数:  2608
  • HTML全文浏览量:  19
  • PDF下载量:  747
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回